Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

• Status: Terminated
• Trial end date: 2017-10-25
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Having successfully completed parent study B7601003.

• Clinical diagnosis of Parkinson's disease.

• Able to refrain from any Parkinson's disease medication not permitted by the protocol.

Exclusion Criteria:

• Female of childbearing potential.

• Severe acute or chronic medical or psychiatric condition or laboratory abnormality.

• Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.